Alnylam Pharmaceuticals Reports Strong First-Quarter Sales for Amvuttra
Alnylam Pharmaceuticals' (ALNY) drug Amvuttra saw sales increase by 187% in the first quarter, reaching $889.9 million, surpassing expectations. The drug, which treats transthyretin amyloidosis, contributed to a significant rise in the company's stock price.
Topics: drug launch pharmaceutical industry sales performance stock price movement